カテゴリ： GlobalData, アメリカ, 企業調査

Charles River Laboratories International Inc (CRL)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Charles River Laboratories International Inc (CRL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9879
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：103
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Charles River Laboratories International Inc (Charles River) is a contract research organization (CRO) that provides essential products and services to accelerate the research, drug discovery and development. It offers various basic research, drug discovery and safety assessment services. The organization also offers clinical, manufacturing and operations and staffing support. It focuses on providing solutions targeted against therapeutic areas of cardiovascular, central nervous system, metabolic inflammation, oncology, ophthalmology, respiratory disease and musculoskeletal disease. Charles River caters its products and services to pharmaceutical and biotechnology companies, government agencies, as well as leading hospitals and academic institutions. It operates through its network facilities located worldwide. Charles River is headquartered in Wilmington, Massachusetts, the US.

Charles River Laboratories International Inc (CRL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Charles River Laboratories International Inc, Medical Devices Deals, 2012 to YTD 2018 12
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
WIL Research Acquires Pharma Services Business Of Ricerca Biosciences 17
Venture Financing 18
KPI Therapeutics Raises USD1.6 Million in Venture Financing 18
Partnerships 19
Charles River Labs and Distributed Bio Enter into Partnership 19
HemaCare and Charles River Laboratories Enter into Partnership 20
Inscopix Enters into Partnership with Brains On-Line 21
Nimbus Therapeutics Enters into Agreement with Charles River Laboratories International 22
Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 23
Charles River Laboratories International Extends Agreement with Genentech 24
Charles River Labs Enters into Agreement with Tri-Institutional Therapeutics Discovery Institute 25
Moderna Therapeutics Enters into Agreement with Charles River Labs 26
Charles River Labs Enters into Agreement with BioMotiv 27
Eisai Extends Research Agreement with Charles River Labs 28
Charles River Labs Expands Agreement with Michael J. Fox Foundation for Parkinson’s Research 29
Charles River Labs Enters into Agreement with Antabio 30
Charles River Labs Enters into Agreement with Pcovery 31
Charles River Labs Enters into Agreement with British Columbia Cancer Agency 32
Charles River Lab Extends Co-Development Agreement with CHDI Foundation 33
BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim 34
MPI Research Enters Into Agreement With inviCRO And 3D Imaging For Drug Discovery And Development 35
BioFocus Extends Agreement With Michael J. Fox Foundation For Parkinson’s Disease 36
Applied StemCell Enters Into Distribution Agreement With Charles River Labs For Genetically Modified Targatt Mouse 37
BioFocus Enters Into Agreement With ChanTest 38
Charles River Labs Expands its Agreement with AstraZeneca 39
Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 40
Activiomics Enters Into Drug Discovery Agreement With BioFocus 41
Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 42
Almirall Enters Into Integrated Drug Discovery Collaboration With BioFocus 43
Licensing Agreements 44
EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 44
Equity Offering 45
Charles River Laboratories International Plans to Raise Funds in Public Offering of Securities 45
Charles River Labs to Invest USD10 Million in BioMotiv 46
Debt Offering 47
Charles River Lab Raises USD500 Million in Private Placement of 5.5% Senior Notes Due 2026 47
Acquisition 48
Charles River Laboratories Acquires MPI Research for USD800 Million 48
Charles River Labs Acquires KWS BioTest for USD24.3 Million 50
Charles River Laboratories Acquires Brains On-Line 51
Quotient Clinical Acquires QS Pharma from Charles River Labs 52
Charles River Laboratories Acquires Agilux Laboratories for USD64.9 Million 53
Charles River Labs Acquires Blue Stream Labs 54
Charles River Laboratories Acquires WIL Research for USD604.8 Million 55
Charles River Labs Acquires Oncotest 57
Charles River Labs Acquires ChanTest from Ampersand Capital for USD59.2 Million 58
MPI Research Acquired Jasper Clinic, Clinical Research Organization 59
Charles River Laboratories Acquires VivoPath 60
Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For USD191.8 Million 61
Charles River Labs Acquires Brass 63
Charles River Labs Completes Acquisition Of 75% Stake In Vital River Labs For US$27 Million 64
Charles River Plans Sale Of The Company 65
Charles River Laboratories International Inc – Key Competitors 66
Charles River Laboratories International Inc – Key Employees 67
Charles River Laboratories International Inc – Locations And Subsidiaries 69
Head Office 69
Other Locations & Subsidiaries 69
Recent Developments 73
Strategy And Business Planning 73
Jun 19, 2018: Charles River Laboratories Joins UConn TIP 73
May 01, 2018: Charles River Laboratories Expands Services for Early Discovery Screening 74
Financial Announcements 75
Nov 07, 2018: Charles River Laboratories announces third-quarter 2018 results 75
Aug 08, 2018: Charles River Laboratories announces second-quarter 2018 results from continuing operations 77
May 10, 2018: Charles River Laboratories Announces First-Quarter 2018 Results from Continuing Operations 79
Feb 13, 2018: Charles River Laboratories Announces Fourth-Quarter 2017 Financial Results 81
Nov 09, 2017: Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations 84
Aug 09, 2017: Charles River Laboratories Announces Second-Quarter 2017 Results from Continuing Operations 86
May 10, 2017: Charles River Laboratories Announces First-Quarter 2017 Results from Continuing Operations 88
Feb 14, 2017: Charles River Laboratories Announces Fourth-Quarter and Full-Year 2016 Results from Continuing Operations and Provides 2017 Guidance 90
Corporate Communications 93
Feb 13, 2018: Charles River Laboratories Announces Executive Management Appointments 93
Jan 16, 2018: Charles River Laboratories Adds Jean-Paul Mangeolle to Board of Directors 94
Jul 05, 2017: Charles River Laboratories Adds Martin Mackay, Ph.D. to Board of Directors 95
Government and Public Interest 96
Oct 16, 2018: Charles River Laboratories awarded five-year, $95.7 million contract by the National Institute of Allergy and Infectious Diseases 96
Product News 97
Apr 03, 2017: Charles River Laboratories Announces Launch of Triple-Immunodeficient Mouse Model for Oncology Research 97
Other Significant Developments 98
Apr 25, 2018: Extending Biomarker Sensitivity with the Quanterix Simoa HD-1 98
Mar 08, 2018: Charles River Laboratories Makes Expansions to Global Biologics Infrastructure 99
Feb 21, 2018: Charles River Laboratories Announces New Tumor Model Compendium 100
Dec 06, 2017: Charles River Adds ERS License to CRISPR/Cas9 Service Offering 101
May 16, 2017: Charles River Laboratories Announces Updates to Oncology Business 102
Appendix 103
Methodology 103
About GlobalData 103
Contact Us 103
Disclaimer 103

List of Tables
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Charles River Laboratories International Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Charles River Laboratories International Inc, Medical Devices Deals, 2012 to YTD 2018 12
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
WIL Research Acquires Pharma Services Business Of Ricerca Biosciences 17
KPI Therapeutics Raises USD1.6 Million in Venture Financing 18
Charles River Labs and Distributed Bio Enter into Partnership 19
HemaCare and Charles River Laboratories Enter into Partnership 20
Inscopix Enters into Partnership with Brains On-Line 21
Nimbus Therapeutics Enters into Agreement with Charles River Laboratories International 22
Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 23
Charles River Laboratories International Extends Agreement with Genentech 24
Charles River Labs Enters into Agreement with Tri-Institutional Therapeutics Discovery Institute 25
Moderna Therapeutics Enters into Agreement with Charles River Labs 26
Charles River Labs Enters into Agreement with BioMotiv 27
Eisai Extends Research Agreement with Charles River Labs 28
Charles River Labs Expands Agreement with Michael J. Fox Foundation for Parkinson’s Research 29
Charles River Labs Enters into Agreement with Antabio 30
Charles River Labs Enters into Agreement with Pcovery 31
Charles River Labs Enters into Agreement with British Columbia Cancer Agency 32
Charles River Lab Extends Co-Development Agreement with CHDI Foundation 33
BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim 34
MPI Research Enters Into Agreement With inviCRO And 3D Imaging For Drug Discovery And Development 35
BioFocus Extends Agreement With Michael J. Fox Foundation For Parkinson's Disease 36
Applied StemCell Enters Into Distribution Agreement With Charles River Labs For Genetically Modified Targatt Mouse 37
BioFocus Enters Into Agreement With ChanTest 38
Charles River Labs Expands its Agreement with AstraZeneca 39
Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 40
Activiomics Enters Into Drug Discovery Agreement With BioFocus 41
Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 42
Almirall Enters Into Integrated Drug Discovery Collaboration With BioFocus 43
EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 44
Charles River Laboratories International Plans to Raise Funds in Public Offering of Securities 45
Charles River Labs to Invest USD10 Million in BioMotiv 46
Charles River Lab Raises USD500 Million in Private Placement of 5.5% Senior Notes Due 2026 47
Charles River Laboratories Acquires MPI Research for USD800 Million 48
Charles River Labs Acquires KWS BioTest for USD24.3 Million 50
Charles River Laboratories Acquires Brains On-Line 51
Quotient Clinical Acquires QS Pharma from Charles River Labs 52
Charles River Laboratories Acquires Agilux Laboratories for USD64.9 Million 53
Charles River Labs Acquires Blue Stream Labs 54
Charles River Laboratories Acquires WIL Research for USD604.8 Million 55
Charles River Labs Acquires Oncotest 57
Charles River Labs Acquires ChanTest from Ampersand Capital for USD59.2 Million 58
MPI Research Acquired Jasper Clinic, Clinical Research Organization 59
Charles River Laboratories Acquires VivoPath 60
Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For USD191.8 Million 61
Charles River Labs Acquires Brass 63
Charles River Labs Completes Acquisition Of 75% Stake In Vital River Labs For US$27 Million 64
Charles River Plans Sale Of The Company 65
Charles River Laboratories International Inc, Key Competitors 66
Charles River Laboratories International Inc, Key Employees 67
Charles River Laboratories International Inc, Subsidiaries 69

List of Figures
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Charles River Laboratories International Inc, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Charles River Laboratories International Inc (CRL)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Konecranes Plc：企業のM&A・事業提携・投資動向
    Konecranes Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Konecranes Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • AdvantEdge Healthcare Solutions Inc：医療機器：M&Aディール及び事業提携情報
    Summary AdvantEdge Healthcare Solutions Inc (AdvantEdge) is a healthcare service provider that offers medical billing, coding and revenue cycle management solutions. The center’s solutions include medical billing, coding, reporting, dashboards and business intelligence, consulting and practice manag …
  • Tenaga Nasional Berhad：発電所・企業SWOT分析
    Tenaga Nasional Berhad – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employ …
  • Ironwood Pharmaceuticals Inc (IRWD)：製薬・医療：M&Aディール及び事業提携情報
    Summary Ironwood Pharmaceuticals Inc (Ironwood) is a commercial biotechnology company that discovers, develops and commercializes medicines for gastrointestinal disorders. The company's major products include Linzess (linaclotide), an oral capsule for the treatment of irritable bowel syndrome with c …
  • Bailian Group Co., Ltd.：企業の戦略的SWOT分析
    Bailian Group Co., Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Jcb Co., Ltd.
    Jcb Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Jcb Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Ricoh Company, Ltd. (7752)：企業の財務・戦略的SWOT分析
    Ricoh Company, Ltd. (7752) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Ok-Q8 AB：企業の戦略的SWOT分析
    Ok-Q8 AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • PledPharma AB (PLED)：企業の財務・戦略的SWOT分析
    Summary PledPharma AB (PledPharma) is a pharmaceutical company that discovers, manufactures, and develops drugs that protect the body against oxidative stress. The company discovers and develops Aladote and PledOx drugs. PledOX drug is used to prevent chemotherapy-induced side effects for colorectal …
  • BioMotiv LLC：医療機器：M&Aディール及び事業提携情報
    Summary BioMotiv LLC (BioMotiv) is a therapeutics licensing and development service provider. The company offers therapeutics across wide disease areas including proteins, small molecules, antibodies, and nucleotides. It portfolio includes psoriasis, inflammatory bowel diseases, cancer, retinitis pi …
  • Emera Inc.：戦略・SWOT・企業財務分析
    Emera Inc. - Strategy, SWOT and Corporate Finance Report Summary Emera Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Merit Medical Systems Inc (MMSI)：企業の製品パイプライン分析2018
    Summary Merit Medical Systems, Inc. (Merit Medical) offers a wide range of single-use medical devices for interventional and diagnostic procedures. The company’s products include inflation devices and accessories, diagnostic and therapeutic catheters, diagnostic and hydrophilic products, thrombolyti …
  • AB Volvo：企業の戦略・SWOT・財務情報
    AB Volvo - Strategy, SWOT and Corporate Finance Report Summary AB Volvo - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Kaefer Isoliertechnik GmbH & Co KG：企業の戦略・SWOT・財務情報
    Kaefer Isoliertechnik GmbH & Co KG - Strategy, SWOT and Corporate Finance Report Summary Kaefer Isoliertechnik GmbH & Co KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • EnBW Energie Baden-Wurttemberg AG (EBK)：電力：M&Aディール及び事業提携情報
    Summary EnBW Energie Baden-Wurttemberg AG (EnBW) is an integrated energy company. Through its subsidiaries, the company generates, procures, transmits, and supplies electricity; and produces, transports and supplies gas. It produces electricity in coal, gas, pumped storage, and nuclear power plants. …
  • SK Biopharmaceuticals Co Ltd-製薬・医療分野：企業M&A・提携分析
    Summary SK Biopharmaceuticals Co Ltd (SK Biopharmaceuticals), a subsidiary of SK Holdings Co Ltd is a developer of drug candidates. The company develops and markets innovative drugs for the treatment of central nervous system. It offers plumiaz, SKL-N05 and JZP-110; YKP3089, relenopride, SKL-PD, SKL …
  • Olink Proteomics AB-医療機器分野：企業M&A・提携分析
    Summary Olink Proteomics AB (Olink) is a biotechnology company that provides products and services for human protein biomarker research. The company’s portfolio of products includes biomarkers, cardiovascular diseases panels, neurological disease panels, inflammation panels and oncology panels. Olin …
  • Traverse Biosciences Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Traverse Biosciences Inc (Traverse Biosciences) is an privately held bioscience company that commercializes drug candidates for the treatment of inflammatory diseases and age-related conditions affecting humans and companion animals. The company provides lead candidate TRB-N0224 which is dev …
  • REVA Medical Inc (RVA)：製品パイプライン分析
    Summary REVA Medical Inc (REVA) is a medical device company that develops minimally invasive medical devices. The company’s product includes bioresorbable polymers. Its bioresorbable polymers can be applied to a variety of medical applications. REVA’s fantom sirolimus-eluting bioresorbable scaffold …
  • Saint-Gobain Weber GmbH：企業の戦略・SWOT・財務情報
    Saint-Gobain Weber GmbH - Strategy, SWOT and Corporate Finance Report Summary Saint-Gobain Weber GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆